SUMMARY
The study is aimed at identifying the key aspects of the national pharmacopeial regulation of the circulation of biotechnological medicines in the Russian pharmaceutical market and at studying the range of major groups based on the analysis of restrictive lists. The systematic analysis of the new national State Pharmacopeia has resulted in the identification of the newly-introduced general pharmacopeia monographs on biotechnological medicines and their groups, establishing the monographs on specific items, and the generalization of the basic conditions for ensuring quality in production. The content analysis of the restrictive lists has made it possible to determine the vital and most important items by the main groups of biotechnological medicines.